Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-801 · 1 trial · 1 indication
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
| Arm | Type | Description |
|---|---|---|
| CX-801 | EXPERIMENTAL | - |
| CX-801 + pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CX-801 | DRUG | Investigational drug |
| pembrolizumab | DRUG | Standard of Care Therapy |
Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (with...
CX-801 is an investigational small molecule being developed for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with an ongoing first-in-human study evaluating its safety and efficacy in patients with advanced solid tumors.
CX-801 targets interferon alpha-2b, a cytokine involved in immune signaling. By modulating this target, the drug aims to exert anti-tumor effects in solid tumors. It is being studied in a Phase 1 clinical trial for adult patients with advanced solid tumors.
CX-801 is being developed by CytomX Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CTMX. The company is conducting a Phase 1 clinical trial of CX-801 in patients with advanced solid tumors.
CX-801 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in a first-in-human trial for advanced solid tumors in adults. The trial is currently recruiting participants in the United States.
CX-801 is being evaluated in a Phase 1 clinical trial with the identifier NCT06462794, titled 'First In Human Study of CX-801 in Advanced Solid Tumors.' This single-arm, controlled study is recruiting 121 adult patients with solid tumors in the United States.
CX-801 is not the same as interferon alpha-2b; rather, it targets interferon alpha-2b. As a small molecule, CX-801 is designed to interact with this cytokine target, which is part of its mechanism of action in treating solid tumors. It is currently in Phase 1 clinical trials.